- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01132222
Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions
June 11, 2010 updated by: Dr. Reddy's Laboratories Limited
A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fed Conditions.
The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg under fed conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare in healthy human adult subjects with the single oral administration under fed conditions with a washout period of 7 days.
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Karnataka
-
Bangalore, Karnataka, India, 560034
- Lotus Labs Pvt. Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (II Underweight and Overweight Min. & Max. Chart)
- Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days to commencement of the study.
- Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
- Informed consent given in written form according to section 10.3 of the protocol.
Female Subjects:
- of child bearing potential practicing an acceptable method of birth control for the duration of study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- postmenopausal for at least 1 year.
- surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.
Exclusion Criteria:
History or presence of significant:
i. Cardiovascular, pulmonary, hepatic, renal hematological; gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
- Alcohol dependence, alcohol abuse or drug abuse within past one year.
- Moderate to heavy smoking (> 10 cigarettes/day) or on assumption of tobacco products.
- History of difficulty in swallowing.
- Clinically significant illness within 4 weeks before the start of the study
- Asthma, urticaria or other allergic type reactions after taking any medication.
Subjects who, through completion of the study, would have donated in excess of
- 500 ml of blood in 14 days, or
- 500 - 800 m l of blood in 14 days (unless approved by the Principal Investigator)
- 1000 ml of blood in 90 days
- 1250 ml of blood in 120 days
- 1500 ml of blood in 180 days
- 2000 ml of blood in 270 days
- 2500 ml of blood in 1 year
- Participation in another clinical trial within the preceding 28 days of study start.
Subjects who have:
- Systolic blood pressure less than 90 mm of Hg and more than 150 mm of Hg
- Diastolic blood pressure less than 60 m of Hg and more than 95 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician/investigator
- Pulse rate below 50/min. and above 105/min.
- Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibuprofen + Psuedoephedrine Hydrochloride
Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
|
Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Other Names:
|
Active Comparator: Advil® Cold and Sinus
Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
|
Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence based on Cmax and AUC parameters
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Vijayanthi G, MBBS, MD, Lotus Labs Pvt. Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Primary Completion (Actual)
October 1, 2004
Study Completion (Actual)
October 1, 2004
Study Registration Dates
First Submitted
May 26, 2010
First Submitted That Met QC Criteria
May 26, 2010
First Posted (Estimate)
May 27, 2010
Study Record Updates
Last Update Posted (Estimate)
June 14, 2010
Last Update Submitted That Met QC Criteria
June 11, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Malnutrition
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Vasoconstrictor Agents
- Nasal Decongestants
- Ibuprofen
- Ephedrine
- Pseudoephedrine
Other Study ID Numbers
- 431-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Ibuprofen + Pseudoephedrine Hydrochloride
-
Reckitt Benckiser Healthcare (UK) LimitedSimbec ResearchCompleted
-
Institut für Pharmakologie und Präventive MedizinPharma Medica Research, Inc.CompletedFever | Pain, Acute | Pain, Back | Pain, HeadCanada
-
Dr. Reddy's Laboratories LimitedCompleted
-
Johnson & Johnson Consumer and Personal Products...Completed
-
Ranbaxy Laboratories LimitedCompleted
-
Perrigo CompanyGlaxoSmithKline; Pfizer; McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. and other collaboratorsCompletedNasal Congestion Associated With the Common ColdUnited States
-
Ranbaxy Laboratories LimitedCompleted
-
GlaxoSmithKlineCompletedSinusitis | Seasonal Allergic RhinitisUnited Kingdom
-
Ache Laboratorios Farmaceuticos S.A.Withdrawn